Review Of Clinical Use Of Monoclonal Antibodies (Bevacizumab)

Sari, Novia Fahrina Purnama and Santi, Made Dwike Swari and Furwanti, Cece and Pratama, Anggara Martha and Ulfa, Farida (2022) Review Of Clinical Use Of Monoclonal Antibodies (Bevacizumab). World Journal of Pharmaceutical Research, 11 (11). pp. 36-45. ISSN 2277– 7105

PDF Novia Fahrina_Review Of Clinical Use Of Monoclonal Antibodies.pdf Download (288kB)

Abstract

Bevacizumab is a humanized monoclonal antibody that has several potentials as a single agent or in combination with a chemotherapeutic agent. The first used in metastatic colorectal cancer (mCRC) therapy, metastatic breast cancer (mBC) therapy, and non-small cell lung cancer (NSCLC) therapy. Furthermore, there is evidence of clinical use for antiangiogenic therapy, as assessed by endothelial cell proliferation and tubule formation and widely accepted as first-line therapy in combination with chemotherapy. Due to the clinical validation of bevacizumab as a specific inhibitor of the interaction between VEGF- A and VEGFR2, the increasing number of monoclonal antibodies in development has targeted VEGFR2 as a promising molecular target for anti-angiogenesis.

Item Type:	Article
Uncontrolled Keywords:	Bevacizumab, monoclonal antibodies, VEGF-A, VEGFR2, and angiogenesis
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Postgraduate Programs > Master Program in Clinical Pharmacy
Depositing User:	Ester Sri W. 196039
Date Deposited:	16 Aug 2022 05:43
Last Modified:	30 Mar 2023 04:10
URI:	http://repository.ubaya.ac.id/id/eprint/42334

Actions (login required)

View Item